Recent Updates
Recently added Catalysts

PTT-121

Phase 1

Healthy Vollunteer | Small molecule | Other |cbdMD, Inc.|Last Updated: Aug 17, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment84

FDA Designations

No designations recorded

Clinical trial landscape

PTT-121 · 1 trial · 1 indication

Phase 1 1
NCT07768176A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PTT-121Healthy Vollunteer
NOT YET_RECRUITING84 Analytics
PHASE1NOT YET_RECRUITING
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PTT-121
Healthy Vollunteer
NCT0776817684
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Treatment-emergent Adverse Events
SAD: up to 15 days MAD: up to 21 days

Secondary Endpoints

Pharmacokinetics of PTT-121
SAD: up to 2 days MAD: up to 7 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
PTT-121 treatmentEXPERIMENTAL -
Placebo treatmentPLACEBO_COMPARATOR -

Interventions

NameTypeDescription
PTT-121DRUGPTT-121 will be administered intravenously
PTT-121 placeboDRUGMatching placebo identical to PTT-121 formulation but without the active pharmaceutical ingredient
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy adults aged between 18 and 55 years. * BMI 18.0-26.0. * Those who are adequate to be subjects in this study upon judgment of the investigator after physical examination, clinical laboratory test, examination, etc. Exclusion Criteria: * History of any clinically signi...

Countries:China
Unlock Eligibility Criteria